Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the target of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 663,500 shares, a decline of 20.5% from the July 15th total of 834,700 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 402,300 shares, the short-interest ratio is presently 1.6 days.
Shares of NAVB opened at $0.72 on Thursday. Navidea Biopharmaceuticals has a 12-month low of $0.49 and a 12-month high of $7.40.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.09). The business had revenue of $0.26 million during the quarter.
In other news, major shareholder John K. Jr. Scott purchased 4,000,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was acquired at an average price of $0.75 per share, for a total transaction of $3,000,000.00. Following the acquisition, the insider now directly owns 5,113,078 shares of the company’s stock, valued at $3,834,808.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu Financial LLC increased its holdings in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,972 shares of the biopharmaceutical company’s stock after buying an additional 90,647 shares during the period. Virtu Financial LLC owned about 0.09% of Navidea Biopharmaceuticals worth $26,000 as of its most recent SEC filing.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Recommended Story: Roth IRA
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.